SEEK ID: https://seek.lisym.org/people/36
Location:
Germany
ORCID: Not specified
Joined: 17th May 2017
LiSyM Pillar II: Chronic Liver Disease Progression (LiSyM-DP) (Molecular Hepatology - Dept of Medicine II - Medical Faculty Mannheim - Heidelberg University) ; LiSyM Pillar III: Regeneration and Repair in Acute-on-Chronic Liver Failure (LiSyM-ACLF) (Molecular Hepatology - Dept of Medicine II - Medical Faculty Mannheim - Heidelberg University)
LiSyM network (Molecular Hepatology - Dept of Medicine II - Medical Faculty Mannheim - Heidelberg University) ; LiSyM PALs (Molecular Hepatology - Dept of Medicine II - Medical Faculty Mannheim - Heidelberg University) ; LiSyM-Krebs Partnering (Molecular Hepatology - Dept of Medicine II - Medical Faculty Mannheim - Heidelberg University)
Related items
- Programmes (2)
- Projects (5)
- Institutions (1)
- Investigations (1+1)
- Studies (1+2)
- Assays (1+5)
- Data files (29+16)
- Publications (62)
- Presentations (24+7)
LiSyM-Krebs ist ein nationales Forschungsnetz zur Früherkennung und Prävention von Leberkrebs, das unter Verwendung des systemmedizinischen Forschungsansatzes die komplexen, dynamischen Prozesse der Krankheitsprogression analysiert, um ausgehend von den Erkenntnissen aus dem Forschungsnetz LiSyM die Entstehung von Leberkrebs besser zu verstehen, vorherzusagen und im besten Fall sogar zu verhindern. LiSyM-Krebs setzt die erfolgreichen Forschungsaktivitäten der BMBF-Vorgängerprogramme ...
Projects: LiSyM-Krebs Partnering, Forschungsnetzwerk LiSyM-Krebs, SMART-NAFLD, DEEP-HCC network, C-TIP-HCC network
Web page: https://www.lisym-cancer.org
Liver Systems Medicine : striving to develop non-invasive methods for diagnosing and treating NAFLD by combining mathematical modeling and biological research. LiSyM, is a multidisciplinary research network, in which molecular and cell biologists, clinical researchers, pharmacologists and experts in mathematical modeling examine the liver in its entirety. LiSyM research focuses on the metabolic liver disease non-alcoholic fatty liver disease (NAFLD), which includes non-alcoholic steatohepatitis ...
Projects: LiSyM Core Infrastructure and Management (LiSyM-PD), LiSyM Pillar I: Early Metabolic Injury (LiSyM-EMI), LiSyM Pillar II: Chronic Liver Disease Progression (LiSyM-DP), LiSyM Pillar III: Regeneration and Repair in Acute-on-Chronic Liver Failure (LiSyM-ACLF), LiSyM Pillar IV: Liver Function Diagnostics (LiSyM-LiFuDi), Model Guided Pharmacotherapy In Chronic Liver Disease (LiSyM-MGP), Molecular Steatosis - Imaging & Modeling (LiSyM-MSIM), The Hedgehog Signalling Pathway (LiSyM-JGMMS), Multi-Scale Models for Personalized Liver Function Tests (LiSyM-MM-PLF), LiSyM PALs, Project Management PTJ, LiSyM network, LiSyM Scientific Leadership Team (LiSyM-LT)
Web page: https://www.lisym.org/
This comprises the whole LiSyM network
Programme: LiSyM: Liver Systems Medicine
Public web page: http://www.lisym.org
Start date: 1st Jan 2016
Organisms: Rattus norvegicus, Rattus rattus, Mus musculus, Homo sapiens
This generic project is intended to be a forum for all LiSyM partner and external stakeholders interested in participating in the BMBF initiative LiSyM-Krebs.
Programme: LiSyM-Krebs - Systemmedizinisches Forschungsnetz zur Früherkennung und Prävention von Leberkrebs
Public web page: https://www.ptj.de/projektfoerderung/gesundheitsforschung/lisym-krebs
Organisms: Not specified
This is a generic project that comprises all LiSyM data management PALs and associated FAIRDOM PALs, as well as the LiSyM data management team. Olga Maja Alain
Programme: LiSyM: Liver Systems Medicine
Public web page: Not specified
Organisms: Not specified
In chronic diseases, at some point the liver can suddenly stop functioning. This is called acute-on-chronic liver failure, or ACLF. This is the leading cause of death in liver patients and is often provoked by the use of transcription or freely available drugs or alcohol abuse. For this condition we need an effective treatment quickly. LiSyM-Pillar III researches the factors that contribute significantly to ACLF. What exactly happens then? Are there any early signs that would enable ACLF to be ...
Programme: LiSyM: Liver Systems Medicine
Public web page: http://www.lisym.org/our-work/pillar-research
Start date: 1st Jan 2016
Organisms: Homo sapiens, Mus musculus, Rattus norvegicus, Rattus rattus
In one in five people with NAFLD, the functioning liver cells, the hepatocytes, are replaced by connective tissue. Eventually this fibrosis becomes irreversible. In this state the liver is like a ‘scar that never heals’. Through it, the liver loses many of its vital functions. LiSyM-Pillar II wants to know more about which factors promote fibrosis and the conditions under which fibrosis becomes irreversible How can fibrosis be diagnosed as early as possible? Researchers in the pillar are also ...
Programme: LiSyM: Liver Systems Medicine
Public web page: http://www.lisym.org/our-work/pillar-research
Start date: 1st Jan 2016
Organisms: Mus musculus, Rattus rattus, Rattus norvegicus, Homo sapiens
Pillar II dooley
Snapshots: No snapshots
Snapshots: No snapshots
Submitter: Seddik Hammad
Assay type: Proteomics
Technology type: FACS
Investigation: Julia/Yan
Study: CCl4 Treatment in mice
Organisms: Mus musculus
SOPs: Sample Collection and Preservation of Blood and...
Data files: Movies for quantification, SAC mice RNA microarray, Supp MM 1, Supp fig 3, Supp fig1, Supp fig2, Supplemental Table 1:, Supplemental Table 2, Supplmentary Materials, Methods, Figures and Ta... and 1 hidden item
Snapshots: No snapshots
Creator: Seddik Hammad
Submitter: Seddik Hammad
Investigations: No Investigations
Studies: No Studies
Assays: No Assays
Proteomic Quantification of the Metabolic Targets in Tumor vs Adjacent Normal Liver Tissues
Creator: Seddik Hammad
Submitter: Seddik Hammad
Investigations: No Investigations
Studies: No Studies
Assays: No Assays
Consistently Altered Metabolic Targets in Human Hepatocellular Carcinoma
Creator: Seddik Hammad
Submitter: Seddik Hammad
Investigations: No Investigations
Studies: No Studies
Assays: No Assays
Creator: Seddik Hammad
Submitter: Seddik Hammad
Investigations: No Investigations
Studies: No Studies
Assays: No Assays
Creator: Seddik Hammad
Submitter: Seddik Hammad
Investigations: No Investigations
Studies: No Studies
Assays: No Assays
Abstract
Authors: Stefan Hoehme, Seddik Hammad, Jan Boettger, Brigitte Begher-Tibbe, Petru Bucur, Eric Vibert, Rolf Gebhardt, Jan G. Hengstler, Dirk Drasdo
Date Published: 2023
Publication Type: Journal
DOI: 10.1016/j.isci.2022.105714
Citation: iScience 26(1):105714
Abstract
Authors: Le Tao, Guangyue Yang, Tiantian Sun, Jie Tao, Chan Zhu, Huimin Yu, Yalan Cheng, Zongguo Yang, Mingyi Xu, Yuefeng Jiang, Wei Zhang, Zhiyi Wang, Wenting Ma, Liu Wu, Dongying Xue, Dongxue Wang, Wentao Yang, Yongjuan Zhao, Shane Horsefield, Bostjan Kobe, Zhe Zhang, Zongxiang Tang, Qigen Li, Qiwei Zhai, Steven Dooley, Ekihiro Seki, Ping Liu, Jianrong Xu, Hongzhuan Chen, Cheng Liu
Date Published: 2023
Publication Type: Journal
DOI: 10.1016/j.jhep.2022.12.031
Citation: Journal of Hepatology,S0168827823000132
Abstract
Authors: Rilu Feng, Kejia Kan, Carsten Sticht, Yujia Li, Shanshan Wang, Hui Liu, Chen Shao, Stefan Munker, Hanno Niess, Sai Wang, Christoph Meyer, Roman Liebe, Matthias P. Ebert, Steven Dooley, Huiguo Ding, Honglei Weng
Date Published: 1st Dec 2022
Publication Type: Journal
DOI: 10.1002/hep.32414
Citation: Hepatology 76(6):1673-1689
Abstract (Expand)
Authors: Guangyue Yang, Liping Zhuang, Tiantian Sun, Yee Hui Yeo, Le Tao, Wei Zhang, Wenting Ma, Liu Wu, Zongguo Yang, Yanqin Yang, Dongying Xue, Jie Zhang, Rilu Feng, Ebert Matthias P., Steven Dooley, Ekihiro Seki, Ping Liu, Cheng Liu
Date Published: 9th Jul 2022
Publication Type: Journal
DOI: 10.1155/2022/1048104
Citation: Canadian Journal of Gastroenterology and Hepatology 2022:1-9
Abstract (Expand)
Authors: Sai Wang, Rilu Feng, Shan Shan Wang, Hui Liu, Chen Shao, Yujia Li, Frederik Link, Stefan Munker, Roman Liebe, Christoph Meyer, Elke Burgermeister, Matthias Ebert, Steven Dooley, Huiguo Ding, Honglei Weng
Date Published: 20th Apr 2022
Publication Type: Journal
DOI: 10.1136/gutjnl-2022-326987
Citation: Gut:gutjnl-2022-326987